Ranbaxy laboratories is currently trading at Rs. 486.50, up by 4.95 points or 1.03% from its previous closing of Rs. 481.55 on the BSE.
The scrip opened at Rs. 479.00 and has touched a high and low of Rs. 490.60 and Rs. 479.00 respectively. So far 62660 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 570.00 on 02-Aug-2011 and a 52 week low of Rs. 366.50 on 19-Dec-2011.
Last one week high and low of the scrip stood at Rs. 490.60 and Rs. 470.15 respectively. The current market cap of the company is Rs. 20535.78 crore.
The promoters holding in the company stood at 63.67% while Institutions and Non-Institutions held 20.47% and 13.82% respectively.
Ranbaxy laboratories and Daiichi Sankyo through its subsidiary Daiichi Sankyo Venezuela S.A. would begin marketing products of Ranbaxy in Venezuela as part of the Hybrid Business Model.
Till now, Ranbaxy has been marketing the products in Venezuela through a local distributor. Daiichi Sankyo Venezuela will now take over this role. To kick off the new arrangement, Daiichi Sankyo Venezuela has already started the promotion of Ranbaxy products starting this month.
Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1837.15 |
| Dr. Reddys Lab | 1271.55 |
| Cipla | 1353.85 |
| Zydus Lifesciences | 1070.90 |
| Lupin | 2351.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: